title: Diffuse large B cell lymphoma: how can we cure more patients in 2012?
abstract: Clinically this chapter will focus on 3 important issues critical in the management of diffuse large B cell lymphoma (DLBCL) in 2012: risk stratification, interim PET-CT scanning and the role of high dose therapy and ASCT in the rituximab era for patients with relapsed and primary refractory disease.
authors.affiliation: Division of Hematologic Oncology, Lymphoma and Adult BMT Services, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, United States. Moskowic@mskcc.org
authors.forename: Craig
authors.initials: C
authors.lastname: Moskowitz
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D064847:Multimodal Imaging; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism; D049268:Positron-Emission Tomography; D011379:Prognosis; D018570:Risk Assessment; D000069283:Rituximab; D055502:Secondary Prevention; D014057:Tomography, X-Ray Computed
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D000069283:Rituximab